EMA starts review of Novavax COVID vaccine

The European Medicines Agency (EMA) said on Wednesday that it received and began evaluating Novavax’s application for conditional marketing authorization of its COVID-19 vaccine, Nuvaxovid.

The agency added it will conduct the review “under an accelerated timeline,” stressing approval could be granted in a matter of weeks in case the data the company submitted are “sufficiently robust and complete to show the efficacy, safety and quality of the vaccine.”

“Today’s announcement from EMA brings Novavax another step closer to our goal of ensuring broad global access to our protein-based COVID-19 vaccine across Europe,” Novavax CEO Stanley Erck commented on the news.



Breaking the News / NP



Source link

About the author: admin Academy

admin

Alcuni articoli sono qui aggregati per darti un'informazione continua e costante, pertanto, sotto ognuno di essi troverai la fonte: entra nel sito di riferimento per avere ulteriori news ed informazioni sull'economia mondiale, ti sarà utile. Ti aspetto nell'Academy!

Get involved!

Fai trading in gruppo!
L'unica Academy di trading completamente gratuita per gli utenti FpMarkets

Comments

Ancora nessun commento